CD40–CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity
about
Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivityAntitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentationSpecific medicinal plant polysaccharides effectively enhance the potency of a DC-based vaccine against mouse mammary tumor metastasisEffect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expressionThe "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.Intracellular transport and peptide loading of MHC class II molecules: regulation by chaperones and motors.Lack of CD4(+) T cells does not affect induction of CD8(+) T-cell immunity against Encephalitozoon cuniculi infection.Immunosuppression without immunosuppression? How to be a tolerant individual in a dangerous world.Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction.Assumptions of the tumor 'escape' hypothesis.Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantationComplementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells.T-cell avidity and tuning: the flexible connection between tolerance and autoimmunity.Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.Inhibition of CD8+ T cell-derived CD40 signals is necessary but not sufficient for Foxp3+ induced regulatory T cell generation in vivo.Multiple roles for CD4+ T cells in anti-tumor immune responses.TNF superfamily: costimulation and clinical applicationsDevelopment of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantationHER-2/neu as a target for cancer vaccines.Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer.Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.The use of agonistic anti-CD40 therapy in treatments for cancer.Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.Immunoglobulin class switch recombination deficiency type 1 or CD40 ligand deficiency: from bedside to bench and back again.Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity.Targeting dendritic cells with antigen via dendritic cell-associated promoters.CD40-activated B cells contribute to mesothelioma tumor regression.Editorial: (CD)40 winks to prevent CD8+ T cell lethargy.Natural T-cell ligands that are created by genetic variants can be transferred between cells by extracellular vesicles
P2860
Q24652244-536B576B-22FE-479D-8CE3-786DD5EC76ECQ27026193-E9E45B28-0979-4233-B935-43ABAE8C0DB1Q27310303-E7E83EBA-2522-4763-AD06-03ABDED5E552Q33486534-5F82C605-4B64-4494-88FF-78C8FCBEF8A3Q33736218-2D89BBF7-7280-4A65-9BAF-1D547B4A540CQ33815425-9EAF2232-D403-4A64-B7E5-AB1371DA62FEQ34004978-9B197E78-58F9-4B84-96B6-71CFDF2A8547Q34294802-0B0CE5E5-565B-44D9-9964-80D14D38FB22Q34433429-EA8E4211-E623-47B2-9C30-FECCF7C3FB0FQ34583258-7499117B-A3A5-49E8-8C73-503F1E97EA4CQ34991001-07A4ED9B-9193-479A-A2B9-B77A638A4808Q36370664-EA4F32E3-7B20-4367-B006-4B9629357E30Q36526360-E2D498C3-EA7E-4B65-873D-A8EE17A06AC6Q36643661-C8562C7D-F890-46B5-8FD4-ED047733E92FQ36958112-5663BE8C-7446-4AD1-91F0-CAAA27841CF0Q37075945-5B695B1B-4D0E-4B86-BC45-495BC21D50E1Q37118150-C4A00944-FC5E-4EC9-A3EC-9F75CB24435FQ37266849-3A3489D7-A06E-4DB6-A08D-6FACCFB0F6F1Q37552067-C677F4D6-6A32-4530-BF9C-2268C8FB1108Q37773255-69A01D37-7E3B-4BE4-AE5A-8C31CD086F1FQ37785948-3C705063-E66D-45D3-ADDF-200566FCEAF0Q37809463-B0D7DF3B-B2D0-451B-B714-320BE7DBF088Q38026924-8ECBA7E1-5E16-4AB9-A0E1-932C39A63204Q38168904-37D9528E-4920-401B-B298-D6CE6EEA77F5Q38168950-A19D0B75-5D9F-4FB3-BBE2-874DC7003D9CQ40409407-9FAA4EFF-F859-434C-A286-D2FCCFCD214DQ42799142-BB1B0903-6859-4C54-A782-EAEF281BCA41Q43406455-E4FCB196-D35B-4351-96A3-27C185B11387Q50952518-BE889DBC-F069-4F96-A6E0-74D93BE99E1FQ58697791-76A782C9-1A06-4902-A3D8-C58B44978EE1
P2860
CD40–CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 1998
@uk
name
CD40–CD40Ligand interactions a ...... riming and anti-tumor immunity
@en
CD40–CD40Ligand interactions a ...... riming and anti-tumor immunity
@nl
type
label
CD40–CD40Ligand interactions a ...... riming and anti-tumor immunity
@en
CD40–CD40Ligand interactions a ...... riming and anti-tumor immunity
@nl
prefLabel
CD40–CD40Ligand interactions a ...... riming and anti-tumor immunity
@en
CD40–CD40Ligand interactions a ...... riming and anti-tumor immunity
@nl
P2093
P356
P1476
CD40–CD40Ligand interactions a ...... riming and anti-tumor immunity
@en
P2093
Cornelis J.M. Melief
Ellen I.H. van der Voort
René E.M. Toes
Rienk Offringa
P304
P356
10.1006/SMIM.1998.0147
P577
1998-12-01T00:00:00Z